Revive Therapeutics Ltd.
RVV
CNSX
| 03/31/2025 | 12/31/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 62.34% | -29.54% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 62.34% | -48.27% | |||
| Operating Income | -62.34% | 48.27% | |||
| Income Before Tax | -54.40% | 24.80% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -54.40% | 24.80% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -54.40% | 24.80% | |||
| EBIT | -62.34% | 48.27% | |||
| EBITDA | -62.34% | 48.27% | |||
| EPS Basic | -66.67% | 25.00% | |||
| Normalized Basic EPS | -20.00% | 0.00% | |||
| EPS Diluted | -66.67% | 25.00% | |||
| Normalized Diluted EPS | -20.00% | 0.00% | |||
| Average Basic Shares Outstanding | 0.00% | 0.00% | |||
| Average Diluted Shares Outstanding | 0.00% | 0.00% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||